ClinicalTrials.gg

Program

pelareorep

Also written as “REOLYSIN®”, “REOLYSIN” and “Pelareorep”.

Its studies are mostly in Neoplasms · Breast Neoplasms · Neoplasm Metastasis · Squamous Cell Carcinoma of Head and Neck · Anus Neoplasms, led by 2 companies.

Furthest: phase 3, since Jul 13, 201014 company-led studies, 2 open or runningNext primary completion: Jul 30, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Oncolytics Biotech132 open or runningphase 3since Jul 13, 2010Jul 16, 2007Jul 30, 2027phase 2 · NCT07280377
Adlai Nortye Biopharma10 open or runningphase 1since Aug 25, 2022Aug 25, 2022none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 16, 2007First study: phase 2 study in OsteosarcomaNew to Oncolytics BiotechOncolytics Biotech · NCT00503295 · 53 enrolled · United States
  2. Sep 10, 2007Phase 1 study in GliomaOncolytics Biotech · NCT00528684 · 18 enrolled · United States
  3. Sep 12, 2008Phase 2 study in Squamous Cell Carcinoma of Head and NeckOncolytics Biotech · NCT00753038 · 14 enrolled · United States
  4. Mar 12, 2009Phase 2 study in Carcinoma, Non-Small-Cell LungOncolytics Biotech · NCT00861627 · 37 enrolled · United States
  5. Sep 24, 2009Phase 2 study in MelanomaOncolytics Biotech · NCT00984464 · 14 enrolled · United States
  6. Oct 15, 20092 phase 2 studies in Neoplasm MetastasisOncolytics Biotech · NCT00998322, NCT00998192
  7. Jul 13, 2010Phase 3 study in Squamous Cell Carcinoma of Head and NeckOncolytics Biotech · NCT01166542 · 167 enrolled · United States, Belgium, Canada and more
  8. Jan 7, 2011Phase 1 study in NeoplasmsOncolytics Biotech · NCT01274624 · 36 enrolled · United States
  9. Nov 25, 2015Phase 1 study in NeoplasmsOncolytics Biotech · NCT02620423 · 11 enrolled · United States
  10. Mar 24, 2016Phase 1 study in NeoplasmsOncolytics Biotech · NCT02723838
  11. Dec 24, 2019Phase 2 study in Breast NeoplasmsOncolytics Biotech · NCT04215146 · 48 enrolled · United States
  12. Aug 25, 2022Adlai Nortye Biopharma's first study: phase 1 study in Breast NeoplasmsNew to Adlai Nortye BiopharmaAdlai Nortye Biopharma · NCT05519059 · 15 enrolled · China
  13. Nov 18, 2025Phase 2 study in Anal Cancer MetastaticOncolytics Biotech · NCT07280377 · 122 enrolled · Germany

Ahead

  1. Jul 30, 2027Primary completion: phase 2 study in Anal Cancer MetastaticOncolytics Biotech · NCT07280377

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 14 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07280377Anal Cancer Metastatic · Germany2Active, not recruitingOncolytics BiotechJul 30, 2027122
NCT05519059Breast Neoplasms · China1CompletedAdlai Nortye BiopharmaSep 29, 202215
NCT04215146Breast Neoplasms · United States2Active, not recruitingOncolytics BiotechAug 1, 202248
NCT02723838Neoplasms1WithdrawnOncolytics BiotechSep 30, 20170
NCT02620423Neoplasms · United States1CompletedOncolytics BiotechMar 201811
NCT01274624Neoplasms · United States1CompletedOncolytics BiotechFeb 201836
NCT01166542Squamous Cell Carcinoma of Head and Neck · United States, Belgium, Canada and more3CompletedOncolytics BiotechApr 2012167
NCT00998322Neoplasm Metastasis · United States2CompletedOncolytics BiotechDec 201334
NCT00998192Neoplasm Metastasis · United States2CompletedOncolytics BiotechSep 201332
NCT00984464Melanoma · United States2CompletedOncolytics BiotechFeb 201414
NCT00861627Carcinoma, Non-Small-Cell Lung · United States2CompletedOncolytics BiotechSep 201537
NCT00753038Squamous Cell Carcinoma of Head and Neck · United States2CompletedOncolytics BiotechJul 201114
NCT00528684Glioma · United States1CompletedOncolytics BiotechApr 201018
NCT00503295Osteosarcoma · United States2CompletedOncolytics BiotechFeb 201153

How it is read

Names in the registry

  • “REOLYSIN®”, 7 entries
  • “REOLYSIN”, 4 entries
  • “Pelareorep”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.